Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Imvax Appoints Sean Hemingway Chief Operating Officer | Contract Pharma
Breaking News, Promotions & Moves

Imvax Appoints Sean Hemingway Chief Operating Officer

Hemingway brings more than 25 years of experience in biological manufacturing and supply chain.

Imvax, Inc., a developer of immunotherapy for Glioblastoma (GBM) and other cancers, has appointed Sean Hemingway as Chief Operating Officer.

Hemingway will lead the expansion of Imvax’s new manufacturing facility at The Curtis and support IT and facilities management functions. He will also oversee the manufacturing and supply organization, while building out Imvax’s cell therapy platform.

“Sean brings invaluable knowledge of project management, manufacturing operations, and network strategy to Imvax,” said John Furey, CEO of Imvax. “His experience will streamline operations, allowing us to refine our antigen-agnostic and proprietary methodology approach to treating tumors with unmet medical needs, helping hundreds of patients across the globe.”

Hemingway has more than 25 years of experience in biological manufacturing and supply chain. He has held both domestic and international positions and played key roles in several corporate integrations. Prior to joining the company, he was senior vice president and global head of the BioLife Plasma Services Business Unit at Takeda. He also held leadership positions at Pfizer, Genzyme, and Baxalta.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters